| Market Capitalization (Millions $) |
460 |
| Shares
Outstanding (Millions) |
47 |
| Employees |
24 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-46 |
| Cash Flow (TTM) (Millions $) |
40 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Benitec Biopharma Inc is a biotechnology company headquartered in California, USA. The company specializes in the development of gene therapy treatments for various diseases using its patented gene-silencing technology called DNA-directed RNA interference (ddRNAi). This technology allows for the suppression or elimination of specific genes associated with diseases, offering a potential cure or treatment.
Benitec Biopharma has a diverse pipeline of therapeutic candidates targeting diseases such as hepatitis B, head and neck squamous cell carcinoma, and ocular diseases. The company's lead product candidate, BB-301, is being developed as a potentially curative treatment for oculopharyngeal muscular dystrophy (OPMD), a rare genetic disease.
The company's approach focuses on creating long-lasting and potentially permanent gene expression changes, providing durable treatment options for patients. In addition to its internal pipeline, Benitec Biopharma also collaborates with research institutions and pharmaceutical companies to further develop and commercialize its gene therapy platform.
Overall, Benitec Biopharma Inc is committed to advancing the field of gene therapy and providing innovative treatments for various diseases using their proprietary ddRNAi technology.
Company Address: 3940 Trust Way Hayward 94545 CA
Company Phone Number: 780-0819 Stock Exchange / Ticker: NASDAQ BNTC
|
0.4%